How PlexusDx Supports a More Personalized Approach PlexusDx's Precision Peptide Genetic Test reveals predispositions in GLP-1 receptor (GLP1R rs6923761), GIPR (rs1800437), and metabolic pathways (FTO rs9939609, MC4R rs17782313) that may help provide context for how your body responds to GLP-1 signaling
These compounds offer the potential for greater convenience, improved tissue penetration, longer half-lives, and lower production costs
However, delivering FAs orally is challenging because they are absorbed before reaching the target site
Targeting development of incretin-producing cells increases insulin secretion
The therapeutic effects of TGR5 agonists could be improved in combinatorial therapy
In addition, all currently available GLP-1R therapies are peptide agonists, most of which require subcutaneous administration [140]